The FDA has granted Breakthrough Therapy designation to GLM101 for phosphomannomutase 2 congenital disorder of glycosylation.

The phase 3 FUSION trial met its primary endpoint, showing ulefnersen significantly improved function and survival in patients with FUS-ALS.

Women with cerebral palsy appear to receive significantly less preventive gynecologic care vs women that do not have cerebral palsy.

Initiating hormone replacement therapy near the onset of menopause may reduce the risk for LATE neuropathological changes in older women.

Continuous activity monitoring with wearable devices reveals that daily step count patterns correlate with disability severity in progressive MS.

The FDA has approved Aqneursa (levacetylleucine) for ataxia in adult and pediatric patients with ataxia-telangiectasia weighing at least 15 kg.

A novel actigraphy-based algorithm accurately measured daytime napping behaviors in patients with narcolepsy type 1 and detected changes during treatment with the orexin receptor 2-selective agonists ...

Children with neurodevelopmental and behavioral disorders may have an increased risk of amblyopia, strabismus, and myopia.

High-frequency spinal cord stimulation significantly reduces pain and improves sensory function related to painful diabetic neuropathy.

Stroke care requires fast action, but neurologists must navigate ethical consent dilemmas to protect patient autonomy under time constraints.

While many in the US are consuming the same amount of microbiome-supportive foods, probiotic supplement use has surged.

Long-term fumarate therapy for multiple sclerosis, compared with anti-CD20 therapy, is linked to a reduced risk for infection.